Phenotypes associated with this allele

• Allele Symbol: Tcra-J^tm1Tgi
• Allele Name: targeted mutation 1, Masaru Taniguchi
• Allele ID: MGI:2180736
• Summary: 9 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Tcra-J^tm1Tgi/Tcra-J^tm1Tgi	B6.129-Tcra-J^tm1Tgi	MGI:3722107
hm2	Tcra-J^tm1Tgi/Tcra-J^tm1Tgi	C.129-Tcra-J^tm1Tgi	MGI:5426352
hm3	Tcra-J^tm1Tgi/Tcra-J^tm1Tgi	involves: 129S1/Sv * 129X1/SvJ	MGI:3813929
hm4	Tcra-J^tm1Tgi/Tcra-J^tm1Tgi	involves: 129S1/Sv * 129X1/SvJ * BALB/c	MGI:4839084
hm5	Tcra-J^tm1Tgi/Tcra-J^tm1Tgi	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:4839085
cx6	Ldlr^tm1Her/Ldlr^tm1Her Tcra-J^tm1Tgi/Tcra-J^tm1Tgi	B6.129-Ldlr^tm1Her Tcra-J^tm1Tgi	MGI:4839086
cx7	Tcra-J^tm1Tgi/Tcra-J^tm1Tgi Tg(Pklr-Myc)73Ak/0	B6.Cg-Tcra-J^tm1Tgi Tg(Pklr-Myc)73Ak	MGI:5430591
cx8	Sh2d1a^tm1Cpt/Sh2d1a^tm1Cpt Tcra-J^tm1Tgi/Tcra-J^tm1Tgi	involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c	MGI:5444640
cx9	Sh2d1a^tm1Cpt/Y Tcra-J^tm1Tgi/Tcra-J^tm1Tgi	involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c	MGI:5444644

Genotype
MGI:3722107

hm1

• Allelic Composition: Tcra-J^tm1Tgi/Tcra-J^tm1Tgi
• Genetic Background: B6.129-Tcra-J^tm1Tgi

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

decreased B cell number ( J:99107 )

• the numbers of CD69+ (a marker for activation) B cells in the spleen are reduced (4.1+/-0.5 compared to 5.1+/-0.7 in wild-type mice)

decreased activated T cell number ( J:99107 )

• the numbers of CD69+ (a marker for activation) T cells in the spleen are reduced (9.9+/-1.8 compared to 16.0+/-3.4 in wild-type mice)

decreased IgE level ( J:121037 )

• anti OVA IgE levels are about one-eighth of control levels after challenge

decreased IgG level ( J:99107 )

• levels of anti CII IgG antibodies are reduced compared to in wild-type mice

decreased circulating interleukin-5 level ( J:121037 )

• 24 hours after OVA challenge

decreased susceptibility to induced arthritis ( J:99107 )

• following induction of arthritis with collagen (CIA) the incidence (40%) and arthritis score (1.5+/-2.2) is reduced compared to wild-type mice (90% incidence with a score of 5.4+/-3.2)

increased incidence of corneal inflammation ( J:132503 )

• marked infiltration of neutrophiles at 24 hours after cauterization

• no further neutrophil or macrophage increases to 96 hours

• increased edema at 96 hours after cauterization

liver inflammation ( J:135830 )

• after BDL, necroinflammatory foci and lymphocytic infiltration are obviously less than in controls

lung inflammation ( J:121037 )

• 42% fewer cells in bronchoalveolar lavage fluid compared to controls after OVA sensitization and challenge

• eosinophiles reduced by 58%

• reduced macrophage and neutrophiles

• normal lymphocyte recruitment

• IL-4 and IL-5 also reduced in bronchoalveolar lavage fluid 24 hours after challenge

homeostasis/metabolism

decreased circulating interleukin-5 level ( J:121037 )

• 24 hours after OVA challenge

decreased circulating alanine transaminase level ( J:135830 )

• one day following bile duct ligation (BDL), serum ALT levels are significantly lower than controls

liver/biliary system

decreased hepatocyte apoptosis ( J:135830 )

• hepatocyte cell death is reduced compared to controls after BDL

liver inflammation ( J:135830 )

• after BDL, necroinflammatory foci and lymphocytic infiltration are obviously less than in controls

abnormal hepatocyte morphology ( J:135830 )

• confluent foci of feathery hepatocyte degeneration due to bile acid cytotoxicity are significantly reduced compared to controls 24 hours after BDL

focal hepatic necrosis ( J:135830 )

• necroinflammatory foci after BDL are reduced in number compared to controls

hematopoietic system

decreased B cell number ( J:99107 )

• the numbers of CD69+ (a marker for activation) B cells in the spleen are reduced (4.1+/-0.5 compared to 5.1+/-0.7 in wild-type mice)

decreased activated T cell number ( J:99107 )

• the numbers of CD69+ (a marker for activation) T cells in the spleen are reduced (9.9+/-1.8 compared to 16.0+/-3.4 in wild-type mice)

decreased IgE level ( J:121037 )

• anti OVA IgE levels are about one-eighth of control levels after challenge

decreased IgG level ( J:99107 )

• levels of anti CII IgG antibodies are reduced compared to in wild-type mice

skeleton

decreased susceptibility to induced arthritis ( J:99107 )

• following induction of arthritis with collagen (CIA) the incidence (40%) and arthritis score (1.5+/-2.2) is reduced compared to wild-type mice (90% incidence with a score of 5.4+/-3.2)

cardiovascular system

decreased susceptibility to induced choroidal neovascularization ( J:138197 )

• area of choroidal neovascularization stimulated by photocoagulation is significantly reduced

vision/eye

decreased susceptibility to induced choroidal neovascularization ( J:138197 )

• area of choroidal neovascularization stimulated by photocoagulation is significantly reduced

increased incidence of corneal inflammation ( J:132503 )

• marked infiltration of neutrophiles at 24 hours after cauterization

• no further neutrophil or macrophage increases to 96 hours

• increased edema at 96 hours after cauterization

abnormal cornea morphology ( J:132503 )

• cauterized area of cornea becomes thickened

cornea opacity ( J:132503 )

• increased opacity relative to controls 24 hours after corneal cauterization

• opacity increases further by 96 hours

reproductive system

abnormal female reproductive system physiology ( J:59892 )

♀ • alpha-galactosylceramide induced abortion does not occur

respiratory system

lung inflammation ( J:121037 )

• 42% fewer cells in bronchoalveolar lavage fluid compared to controls after OVA sensitization and challenge

• eosinophiles reduced by 58%

• reduced macrophage and neutrophiles

• normal lymphocyte recruitment

• IL-4 and IL-5 also reduced in bronchoalveolar lavage fluid 24 hours after challenge

decreased airway responsiveness ( J:121037 )

• less airway hypersensitive response develops after OVA sensitization and challenge

cellular

decreased hepatocyte apoptosis ( J:135830 )

• hepatocyte cell death is reduced compared to controls after BDL

Genotype
MGI:5426352

hm2

• Allelic Composition: Tcra-J^tm1Tgi/Tcra-J^tm1Tgi
• Genetic Background: C.129-Tcra-J^tm1Tgi

Il17rb^tm1Tgi/Il17rb^tm1Tgi and Tcra-J^tm1Tgi/Tcra-J^tm1Tgi mice fail to exhibit airway hyperactivity in response to respiratory syncytial virus exposure

immune system

abnormal interleukin secretion ( J:184570 )

• the bronchoalveolar lavage fluid from mice exposed to respiratory syncytial virus fail to exhibit an increase in IL5, IL9, IL10, IL13, IL17A and IL22 unlike wild-type mice

decreased interleukin-10 secretion ( J:184570 )

decreased interleukin-13 secretion ( J:184570 )

• the bronchoalveolar lavage fluid from mice exposed to respiratory syncytial virus

decreased interleukin-17 secretion ( J:184570 )

• the bronchoalveolar lavage fluid from mice exposed to respiratory syncytial virus

decreased interleukin-5 secretion ( J:184570 )

• the bronchoalveolar lavage fluid from mice exposed to respiratory syncytial virus

decreased interleukin-9 secretion ( J:184570 )

• the bronchoalveolar lavage fluid from mice exposed to respiratory syncytial virus

respiratory system

decreased airway responsiveness ( J:184570 )

• in response to respiratory syncytial virus exposure, mice fail to exhibit airway hyperreactivity unlike wild-type mice

• however, the response could be restored by transfer of wild-type invariant NK T cells

Genotype
MGI:3813929

hm3

• Allelic Composition: Tcra-J^tm1Tgi/Tcra-J^tm1Tgi
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ

cardiovascular system

cardiovascular system phenotype ( J:134875 )

N • mice exhibit normal arteriogenesis following occlusion

immune system

decreased circulating interferon-gamma level ( J:155199 )

• IFN gamma is not induced by LPS administration in Propionibacterium acnes primed mice

decreased interferon-gamma secretion ( J:155199 )

• decreased production by CD4 T-cells after exposure to heat killed Propionibacterium acnes

decreased susceptibility to bacterial infection ( J:155199 )

• expression data indicates absence of liver damage in response to LPS administration in Propionibacterium acnes primed

homeostasis/metabolism

decreased circulating interferon-gamma level ( J:155199 )

• IFN gamma is not induced by LPS administration in Propionibacterium acnes primed mice

Genotype
MGI:4839084

hm4

• Allelic Composition: Tcra-J^tm1Tgi/Tcra-J^tm1Tgi
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * BALB/c

respiratory system

abnormal airway responsiveness ( J:84720 )

• hyper-reactivity does not develop in response to OVA challenge

immune system

abnormal eosinophil cell number ( J:84720 )

• substantial reduction in airway eosinophilia in response to OVA challenge

abnormal immune serum protein physiology ( J:84720 )

decreased IgE level ( J:84720 )

• decreased OVA specific IgE in serum of OVA challenged mice

abnormal interleukin secretion ( J:84720 )

decreased interleukin-13 secretion ( J:84720 )

• less IL-13 found in bronchial lymph nodes of OVA challenged mice

decreased interleukin-4 secretion ( J:84720 )

• less IL-4 found in bronchial lymph nodes of OVA challenged mice

liver inflammation ( J:105977 )

• resistant to the IL-12 induced increase in mononuclear cells after partial hepatectomy seen in controls

liver/biliary system

liver inflammation ( J:105977 )

• resistant to the IL-12 induced increase in mononuclear cells after partial hepatectomy seen in controls

impaired liver regeneration ( J:105977 )

• IL-12 fails to cause any liver damage beyond that caused by partial hepatectomy

hematopoietic system

abnormal eosinophil cell number ( J:84720 )

• substantial reduction in airway eosinophilia in response to OVA challenge

decreased IgE level ( J:84720 )

• decreased OVA specific IgE in serum of OVA challenged mice

Genotype
MGI:4839085

hm5

• Allelic Composition: Tcra-J^tm1Tgi/Tcra-J^tm1Tgi
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

mortality/aging

increased susceptibility to xenobiotic induced morbidity/mortality ( J:89695 )

• alpha-galactosylceramide has no protective effect against bleomycin induced mortality

• 65% die by the 28th day

respiratory system

lung inflammation ( J:89695 )

• initial development of pulmonary inflammation develops after bleomycin administration in mice treated with alpha-galactosylceramide just as in controls

pulmonary fibrosis ( J:89695 )

• develops after bleomycin administration in mice treated with alpha-galactosylceramide just as in controls

hematopoietic system

decreased NK T cell number ( J:89695 )

• no NKT cells are found in the lungs after bleomycin administration

liver/biliary system

abnormal liver morphology ( J:93915 )

• considerably less liver damage induced by concanavalin A injection than in controls

• as measured by alanine transaminase levels

• reduced concanavalin A induced histological damage

homeostasis/metabolism

increased susceptibility to xenobiotic induced morbidity/mortality ( J:89695 )

• alpha-galactosylceramide has no protective effect against bleomycin induced mortality

• 65% die by the 28th day

decreased physiological sensitivity to xenobiotic ( J:93915 )

• considerably less liver damage induced by concanavalin A injection than in controls

• as measured by alanine transaminase levels

• reduced concanavalin A induced histological damage

immune system

decreased NK T cell number ( J:89695 )

• no NKT cells are found in the lungs after bleomycin administration

lung inflammation ( J:89695 )

• initial development of pulmonary inflammation develops after bleomycin administration in mice treated with alpha-galactosylceramide just as in controls

Genotype
MGI:4839086

cx6

• Allelic Composition: Ldlr^tm1Her/Ldlr^tm1Her; Tcra-J^tm1Tgi/Tcra-J^tm1Tgi
• Genetic Background: B6.129-Ldlr^tm1Her Tcra-J^tm1Tgi

cardiovascular system

decreased susceptibility to atherosclerosis ( J:140276 )

• lesions in the ascending aorta are reduced 20% in males and 28% in females relative to homozygous Ldlr^tm1Her

• considerable reduction of lipid containing areas in the lesions

• less IFN-gamma in the lesions

immune system

decreased interferon-gamma secretion ( J:140276 )

• less IFN-gamma in atherosclerotic lesions

Genotype
MGI:5430591

cx7

• Allelic Composition: Tcra-J^tm1Tgi/Tcra-J^tm1Tgi; Tg(Pklr-Myc)73Ak/0
• Genetic Background: B6.Cg-Tcra-J^tm1Tgi Tg(Pklr-Myc)73Ak

neoplasm

increased metastatic potential ( J:184496 )

• 40% of double mutants exhibit lung metastasis which is not seen in single Tg(Pklr-Myc)73Ak mice

increased malignant tumor incidence ( J:184496 )

• tumors have higher grades of malignancy and are less differentiated than those of single Tg(Pklr-Myc)73Ak mice

increased hepatocellular carcinoma incidence ( J:184496 )

• mutants develop hepatocellular carcinoma (HCC); stronger promotion of initiation and progression steps of HCC development compared to single Tg(Pklr-Myc)73Ak mice

• the number and size of tumor nodules in double mutants is greater than in single Tg(Pklr-Myc)73Ak mice

• some tumors in double mutants exhibit a very poorly differentiated phenotype (fetal-like phenotype) that is never seen in tumors of single Tg(Pklr-Myc)73Ak mice

• tumors have higher mitotic indices compared with tumors from single Tg(Pklr-Myc)73Ak mice

liver/biliary system

increased hepatocellular carcinoma incidence ( J:184496 )

• mutants develop hepatocellular carcinoma (HCC); stronger promotion of initiation and progression steps of HCC development compared to single Tg(Pklr-Myc)73Ak mice

• the number and size of tumor nodules in double mutants is greater than in single Tg(Pklr-Myc)73Ak mice

• some tumors in double mutants exhibit a very poorly differentiated phenotype (fetal-like phenotype) that is never seen in tumors of single Tg(Pklr-Myc)73Ak mice

• tumors have higher mitotic indices compared with tumors from single Tg(Pklr-Myc)73Ak mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
hepatocellular carcinoma		DOID:684	OMIM:114550	J:184496

Genotype
MGI:5444640

cx8

• Allelic Composition: Sh2d1a^tm1Cpt/Sh2d1a^tm1Cpt; Tcra-J^tm1Tgi/Tcra-J^tm1Tgi
• Genetic Background: involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c

immune system

decreased germinal center B cell number ( J:189126 )

♀ • following immunization with NP-KLH

decreased IgG level ( J:189126 )

♀ • of NP-specific IgG following immunization with NP-KLH that is more severe than in Sh2d1a^tm1Cpt homozygotes on a similar background

hematopoietic system

decreased germinal center B cell number ( J:189126 )

♀ • following immunization with NP-KLH

decreased IgG level ( J:189126 )

♀ • of NP-specific IgG following immunization with NP-KLH that is more severe than in Sh2d1a^tm1Cpt homozygotes on a similar background

Genotype
MGI:5444644

cx9

• Allelic Composition: Sh2d1a^tm1Cpt/Y; Tcra-J^tm1Tgi/Tcra-J^tm1Tgi
• Genetic Background: involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c

hematopoietic system

decreased germinal center B cell number ( J:189126 )

♂ • following immunization with NP-KLH

decreased IgG level ( J:189126 )

♂ • of NP-specific IgG following immunization with NP-KLH that is more severe than in Sh2d1a^tm1Cpt homozygotes on a similar background

immune system

decreased germinal center B cell number ( J:189126 )

♂ • following immunization with NP-KLH

decreased IgG level ( J:189126 )

♂ • of NP-specific IgG following immunization with NP-KLH that is more severe than in Sh2d1a^tm1Cpt homozygotes on a similar background